Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06243757

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Participants will a diagnosis of gastroesophageal junction (GEJ) adenocarcinoma and will have either a minimally invasive proximal gastrectomy (MIPG) or a minimally invasive total gastrectomy (MITG) as part of their routine care. Participants with complete a questionnaire 1 month before the surgical procedure and then 1, 3, 6 and 12 months after the surgical procedure.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms GastroEsophageal Cancer Gastroesophageal Junction Adenocarcinoma Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to speak and read English, Spanish, Japanese or Korean
  • Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
  • Age ≥ 18

Exclusion criteria

  • Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
  • Patients with known narcotic dependence, with average daily dose > 5 mg oral morphine equivalent
  • Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
  • Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Treatment and study plan

MDASI-GI

Other

The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:

constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated

Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine).

Other names: MD Anderson Symptom Inventory for gastrointestinal cancer

Primary outcomes

  1. Appetite level score according to the MDASI-GI

    Time frame: 3 months after surgery

    The primary outcome is the appetite level score (with 0 being the best and 10 being the worst) according to the MDASi-GI at 3 months after surgery

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Registry information

Official study title

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Important dates

Study start
2024
Primary completion
2036
Study completion
2036
First posted
Feb 6, 2024
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.